Holding company atop Amorepacific Corp, Korea's top cosmetics maker behind Sulwhasoo, Innisfree and Laneige.
Holding company atop Amorepacific Corp, Korea's top cosmetics maker behind Sulwhasoo, Innisfree and Laneige.
Holds shares in Amorepacific Corp and other group companies, so its own income is dividends and brand-royalty payments from them, and its consolidated results largely mirror the operating company. Created in 2007 when the group split into a holding company and an operating company, and controlled by the founding Suh family.
Moat: none. Pure holding company; value depends on operating subsidiary Amorepacific Corp.
Headquarters: Seoul, South Korea · Founded: 2006 · Employees: 60
Size AMOREPACIFIC (002790.KS) is a South Korea Consumer Staples company (Household/Personal Care) with a market value of $1.61B, the 164th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩27,000 on 18 Nov 2026.
Performance Over six months the shares gained 1.9%, against +7.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 8.6% over the last twelve months (peer median +5.6%); the operating margin is 9.0% (peer median 10.5%).
Valuation It trades at 8.5× forward earnings against a peer median of 19.0× (cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.1 points below its cost of capital (5.4% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩4.94T | ₩4.62T | ₩4.26T | ₩4.02T | ₩4.49T |
| Revenue growth | — | +9% | +6% | -11% | — |
| Gross profit | ₩3.47T | ₩3.13T | ₩2.87T | ₩2.67T | ₩2.91T |
| EBITDA | ₩714B | ₩648B | ₩517B | ₩411B | ₩595B |
| Net income | ₩134B | ₩104B | ₩230B | ₩119B | ₩62.2B |
| Free cash flow | ₩431B | ₩553B | ₩297B | ₩202B | ₩63.8B |
| Capital expenditure | ₩124B | ₩107B | ₩117B | ₩232B | ₩160B |
| Total debt | ₩263B | ₩346B | ₩452B | ₩374B | ₩367B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| AMOREPACIFIC 002790.KS | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% |
| LG H&h 051900.KS | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002790.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.7% | +1.1% | 7th highest of 21 |
| 6-month return | +1.9% | +7.1% | 10th lowest of 21 |
| Distance from 52-week high | -23.9% | -26.2% | 9th highest of 21 |
| Revenue growth (TTM) | +8.6% | +5.6% | 9th highest of 21 |
| Operating margin | 9.0% | 10.5% | 9th lowest of 21 |
| Forward P/E | 8.5× | 19.0× | cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -5.7% | 3.4% | 4th least demanding of 17 |
| Growth delivered (Del g) | -1.3% | +13.4% | 2nd lowest of 17 |
| Hurdle (Req g minus delivered) | -4.4 pp | -5.9 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | -1.1 pp | +6.8 pp | 5th lowest of 20 |
| EV / EBITDA | 6.3× | 10.2× | 2nd cheapest of 15 |
| Net debt / EBITDA | -2.1× | -1.2× | 5th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| Pigeon 7956.T | Japan | $1.76B | +26% | +8% | 13% | 27.9× | -2.4% | +1.9% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Energizer ENR | United States | $1.94B | +71% | 0% | 17% | 9.1× | -5.1% | -0.5% |
| Emami EMAMILTD.NS | India | $1.94B | -5% | +13% | 20% | 23.4× | 21.5% | +5.6% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| Pola Orbis 4927.T | Japan | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% | -0.7% |
| Kolmar Korea 161890.KS | South Korea | $2.05B | +14% | +16% | 10% | 14.3× | -1.6% | +15.5% |
| Blue Moon 6993.HK | Hong Kong | $2.07B | -4% | -2% | -2% | 103.3× | n/a | n/a |
| KOSE 4922.T | Japan | $2.16B | +16% | +4% | 5% | 29.9× | n/a | n/a |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% | +21.2% |
| d'Alba Global 483650.KS | South Korea | $1.13B | -55% | +49% | 22% | 12.0× | -6.6% | +53.0% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.04B | +15% | +74% | 18% | 11.8× | 11.3% | +49.0% |